Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

NCT ID: NCT03175744

Last Updated: 2023-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-24

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to demonstrate the safety and effectiveness of the Stellarex DCB for the treatment of stenosis or occlusions of below-the-knee arteries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Limb Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stellarex DCB

Spectranetics Stellarex Drug Coated Balloon

Group Type EXPERIMENTAL

Stellarex DCB

Intervention Type DEVICE

Intervention with the Stellarex DCB

PTA Catheter

Standard Uncoated Balloon Angioplasty Catheter

Group Type ACTIVE_COMPARATOR

PTA Catheter

Intervention Type DEVICE

Intervention with an uncoated Standard PTA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stellarex DCB

Intervention with the Stellarex DCB

Intervention Type DEVICE

PTA Catheter

Intervention with an uncoated Standard PTA

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Rutherford Clinical Category 4-5
* Life expectancy \> 1 year
* Significant stenosis ≥70%
* Patent inflow artery
* Target vessel(s) diameter between 2 and 4 mm
* Target vessel(s) reconstitute(s) at the ankle

Exclusion Criteria

* Pregnant or planning to become pregnant
* History of stroke within 3 months
* Planned major amputation
* eGFR \<30
* Acute limb ischemia
* Prior stent placement in target lesion
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Philips Healthcare

INDUSTRY

Sponsor Role collaborator

Spectranetics Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Gray, MD

Role: PRINCIPAL_INVESTIGATOR

Lankenau Heart Institute

Mahmood K Razavi, MD

Role: PRINCIPAL_INVESTIGATOR

Vascular and Interventional Specialists of Orange

Dierk Scheinert, MD

Role: PRINCIPAL_INVESTIGATOR

University of Leipzig

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Joseph Hospital

Orange, California, United States

Site Status

Bradenton Cardiology Center

Bradenton, Florida, United States

Site Status

Cardiovascular Institute of the South

Houma, Louisiana, United States

Site Status

Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

University Hospitals, Cleveland Medical Center

Cleveland, Ohio, United States

Site Status

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, United States

Site Status

Pinnacle Health Cardiovascular Institute

Wormleysburg, Pennsylvania, United States

Site Status

Greenville Health System

Greenville, South Carolina, United States

Site Status

Flinders Medical Center

Bedford Park, , Australia

Site Status

Sir Charles Gairdner Hospital

Perth, , Australia

Site Status

LKH Universitatsklinik Graz

Graz, , Austria

Site Status

Medizinische Universitat Wien

Vienna, , Austria

Site Status

Imelda Ziekenhuis

Bonheiden, , Belgium

Site Status

ZOL St. jan

Genk, , Belgium

Site Status

University Hospital Gent

Ghent, , Belgium

Site Status

Klinikum Hoschsauerland GmbH

Arnsberg, , Germany

Site Status

Universitats-Herzzentrum Freiburg-Bad Krozingen

Bad Krozingen, , Germany

Site Status

SRH Klinikum Karlsbad

Karlsbad, , Germany

Site Status

Universitatsklink Leipzig

Leipzig, , Germany

Site Status

University Hospital of Tuebingen

Tübingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D032150

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug Coated Balloons for Prevention of Restenosis
NCT00696956 UNKNOWN PHASE2/PHASE3